Sandoz – a gold sponsor of the Joint Congress of ESPE and ESE 2025.
At Sandoz, we’re proud to be a pioneer in the development of biosimilars.
With eleven marketed biosimilars and a broad and deep pipeline, we have more biosimilar products reaching more patients than any other company.
We’re proud to lead the way with biosimilars. We started the world’s first ever biosimilar development program in 1996 and we were the first company to receive approval for a biosimilar in Europe, Japan, Canada, and the US.
Today, with a powerful pipeline of biosimilars, we’re creating a brighter future for even more patients.
Find us on booth E.21 in the exhibition hall E.
All further details below will be available on the Congress webpage too.
Congress activities
Sunday 11 May 2025, 15:55–16:55 CEST, Room C1
Challenges in the diagnosis and management of patients with DSD: A perspective from childhood to adulthood. A Sandoz sponsored satellite symposium.
Chair: Marta Ramón Krauel, Spain
Challenges in the diagnosis and management of DSD patients during adolescence
Hedi Claahsen-van der Grinten, The Netherlands
Challenges in the follow up of DSD patients in adulthood
Claus Gravholt, Denmark
